

Court Approved Legal Notice
**NOTICE OF ALLOCATION AND DISTRIBUTION PLAN FOR
STATE ATTORNEYS GENERAL GENERIC PRESCRIPTION DRUG SETTLEMENTS**

If you bought certain generic prescription drugs in the United States between May 1, 2009, and December 31, 2019, you could receive money from State Attorneys General Settlements by submitting an eligible claim by March 8, 2027.

*A federal court directed this Notice.
This is not a solicitation from a lawyer.*

- Multiple settlements have been reached with some generic prescription drug manufacturers in three consumer protection and antitrust lawsuits originally brought by Attorneys General of 50 states, commonwealths, or U.S. territories, and the District of Columbia against a large number of the nation's largest generic drug manufacturers ("States' Actions"). The lawsuits are being pursued by the attorneys general of Connecticut, Alaska, Arizona, California, Colorado, District of Columbia, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming (the "State Attorneys General") to recover restitution for their consumers who bought certain prescription drugs ("Drugs at Issue").
- The State Attorneys General have accumulated Consumer Restitution Funds from settlements reached in the States' Actions and have proposed an Allocation and Distribution Plan to distribute the Consumer Restitution Funds to Eligible Consumers who submit timely claim forms.
- You may be eligible to receive payment if you are an individual who bought one or more Drugs at Issue in the U.S. between May 1, 2009, and December 31, 2019 ("Time Period"); did not buy them for resale or directly from any Defendant; are not an officer, director, management, or employee of any Defendant; and currently reside in a state, commonwealth, or territory that is a party to one or more settlements, or you currently reside in Alabama, Arkansas, Hawaii, or Texas (for Apotex-only eligibility). Eligibility is based on where you reside when you submit your claim, not where you made your purchases.
- To receive payment, you must submit a valid, signed, and completed Claim Form certifying eligibility and purchases of at least one Drug at Issue during the Time Period. The deadline for submitting a Claim is **March 8, 2027**. You may submit online at AGGenericDrugsClaims.com or download a form from the settlement website AGGenericDrugs.com and mail it to the Claims Administrator at the address on the form. Only valid claims submitted by the Claims Deadline will be included in the Initial Distribution; however, late valid claims may be considered for future distributions. Payments will be made after the Claims Deadline passes, claims are reviewed, disputes are resolved, and the Court grants final approval of the Allocation and Distribution Plan.
- This Notice is a summary and not intended to set forth all the details of the Allocation and Distribution Plan. For additional information and important documents visit the website AGGenericDrugs.com or call 1-866-290-0182.

**YOUR LEGAL RIGHTS AND OPTIONS
RELATING TO THE ALLOCATION AND DISTRIBUTION PLAN**

SUBMIT A CLAIM	By submitting a completed, signed, valid, and timely Claim Form by March 8, 2027 demonstrating eligibility to receive payment from one or more settlements, you will receive payment when the Initial Distribution is determined and approved by the Court. Your payment will depend on your eligibility and the option you chose on the Claim Form.	To receive any payment under the proposed Allocation and Distribution Plan you must submit a completed, signed Claim Form certifying eligibility and purchases during the Time Period. The Claims Deadline for the Initial Distribution is March 8, 2027 . You may submit online at AGGenericDrugsClaims.com or download a form and mail it to the Claims Administrator at the address on the form. Only valid claims submitted by the Claims Deadline will be included in the Initial Distribution, and late valid claims may be considered for future distributions.
REGISTER TO RECEIVE FUTURE NOTICES	You will receive updates about the lawsuits, settlements, and allocation and distribution process. Claim forms will also be made available via the website, AGGenericDrugs.com or by calling 1-866-290-0182.	
DO NOTHING NOW	If you do not submit a Claim Form by the Claims Deadline, you will not receive any payment in the planned Initial Distribution.	You may submit a Claim Form at a later date to be considered in any future distributions. If you do not register your contact information via the website or as otherwise provided (below), you may not receive notice about future distributions and thereby may lose any ability to receive any payment from the Settlements.
EXCLUDE YOURSELF	You will not receive a payment from the Settlements.	To exclude yourself from the Allocation and Distribution Plan and the States' Actions you must either go to the website (AGGenericDrugs.com) and fill out the requisite information, or alternatively, mail a written statement to the settlement administrator as detailed below. To be timely, you must take action to exclude yourself by opting out no later than August 14, 2027 .
OBJECT TO THE ALLOCATION AND DISTRIBUTION PLAN	If you do not exclude yourself, you can write to the Court explaining why you disagree with the Allocation and Distribution Plan, or otherwise comment on the Allocation and Distribution Plan.	To object to any aspect of the Allocation and Distribution Plan or otherwise express concerns about the Allocation and Distribution Plan or the States' Actions – but still be included in the Settlements and the States' Actions – you must submit a written statement to the Court and counsel (see instructions below). To be timely, you must submit the objection so that it is received by the Court no later than August 14, 2027 .
GO TO THE HEARING	Ask to speak in Court about your opinion of the Allocation and Distribution Plan.	September 8, 2027

These rights and options – **and the deadlines to exercise them** – are explained in this Notice.

WHAT THIS NOTICE CONTAINS

BASIC INFORMATION.....	4
1. What Is This Notice About?	4
2. What Are the Lawsuits About?	4
3. Who Are Settling Defendants?	4
4. What Is the Allocation and Distribution Plan?	5
WHO IS ELIGIBLE UNDER THE PLAN.....	5
5. How Do I Know if I Am Eligible to Receive Payment?	5
6. What Drug Purchases Qualify?	6
7. What Purchases Do Not Qualify?	6
8. Who Are the Defendants?	6
THE STATES' LITIGATION.....	7
9. Why Are the Lawsuits Continuing if There Are Settlements?	7
THE CLAIMS PROCESS.....	7
10. How Do I Participate in the Distribution?	7
11. What Is the Deadline for Submitting a Claim?	7
12. How Do I Submit a Claim?	7
13. What Information Do I Need to Provide to Submit a Claim?	7
14. Do I Need to Submit Receipts?	8
THE DISTRIBUTION OF PAYMENTS.....	8
15. How Much Money Will I Receive?	8
16. How Will I Get My Payment?	9
17. When Will I Get My Payment?	9
18. Does My Payment Expire?	9
THE CLAIMS REVIEW PROCESS AND DENIAL OF CLAIMS	9
19. What Happens if My Claim Is Incomplete or Deficient?	9
20. If My Claim Is Denied, Can I Appeal a Denial?	10
FUTURE DISTRIBUTIONS	10
21. Will There Be Additional Distributions or Payments?	10
22. Do I Need to Submit Another Claim Form for Future Distributions?	10
23. What If I Move After I Submit a Claim?	10
REMAINING IN THE STATES ACTIONS	10
24. What Am I Giving Up If I Stay in the States' Actions?	10
EXCLUDE YOURSELF FROM THE ALLOCATION AND DISTRIBUTION PLAN	11
25. What If I Do Not Want to Be Part of the Allocation and Distribution Plan?	11
26. What If I Do Not Want to Be Included in the States' Litigation?	11
OBJECTING TO THE ALLOCATION AND DISTRIBUTION PLAN.....	12
27. How Do I Object to the Allocation and Distribution Plan?	12

28. What Is the Difference Between Objecting to the Allocation and Distribution Plan and Excluding Myself from the Allocation and Distribution Plan and States’ Actions?.....	13
THE FINAL APPROVAL HEARING	13
29. When and Where Will the Court Decide Whether to Approve the Allocation and Distribution Plan?	13
30. Do I Have to Attend the Final Approval Hearing?.....	14
31. Can I Attend the Final Approval Hearing?.....	14
GET MORE INFORMATION	14
32. Where Can I Get More Information?	14
DRUGS AT ISSUE	16

BASIC INFORMATION

1. What Is This Notice About?

This Notice is to inform you about a proposed Allocation and Distribution Plan for the allocation and distribution of Consumer Restitution Funds recovered by the State Attorney General from settlements reached in the States’ Actions with some Defendants (the “Settlements”) *before* the Court decides whether to approve the Allocation and Distribution Plan, so that you may determine whether to take steps to opt out, object, or otherwise protect your rights. This Notice explains the lawsuits, the Allocation and Distribution Plan, and your legal rights.

The court in charge is the United States District Court for the District of Connecticut. The lawsuits at issue are *State of Connecticut et al. v. Aurobindo Pharma USA, Inc. et al.*, No. 16-cv-02056 (D. Conn.); *State of Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al.*, No. 19-cv-00710 (D. Conn.); and *State of Connecticut et al. v. Sandoz, Inc. et al.*, No. 20-cv-00802 (D. Conn.) (collectively referred to as “States’ Actions”). The State Attorneys General that sued are called Plaintiffs, and the companies they sued are called the Defendants.

2. What Are the Lawsuits About?

The lawsuits claim that numerous Defendants and their alleged co-conspirators agreed to fix prices and split customers for prescription drugs sold in the United States. As a result, consumers who bought certain generic prescription drugs (“Drugs at Issue”) may have paid more than they should have. The Defendant drug manufacturers deny they did anything wrong. Some Defendants have agreed to settle the case with no admission of liability (“Settling Defendants”). The lawsuits are not about – and do not question – the safety or effectiveness of any of the Drugs at Issue.

3. Who Are Settling Defendants?

The Settling Defendants are Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals Ltd., and Satish Mehta (“Heritage Settlement”), Apotex Corp. (“Apotex Settlement”), Bausch Health US, LLC and Bausch Health Americas, Inc. (“Bausch Settlement”), Lannett Company, Inc. (“Lannett Settlement”), and Glenmark Pharmaceuticals, Inc., USA. (“Glenmark Settlement”) (pending Court approval as of 7/31/26).

Other defendants include Actavis, Amneal, Ascend, Aurobindo, Breckinridge, Citron, Dr. Reddy's, Fougera (see Sandoz), G&W, Greenstone, Lupin, Mallinckrodt, Mayne Pharma, Mylan, Par Pharmaceutical (Endo bankruptcy), Perrigo, Pfizer, Sandoz, Sun, Taro, Teligent, Teva, Upsher-Smith, Valeant, Wockhardt, and Zydus.

A full list of the Defendants and the Drugs at Issue in this litigation and Settlements is available at www.AGGenericDrugs.com.

4. What Is the Allocation and Distribution Plan?

The Plaintiff States propose this Plan of Allocation and Distribution to allocate Consumer Restitution Funds received in multiple settlements in the States' Actions to Eligible Consumers who submit timely Claim Forms and whose claims are accepted. The Plan is designed to be efficient, fair, and reasonable, and to facilitate consumer participation.

The Settlements provide that Settling Defendants will make monetary payments of which roughly 45% is allocated to restitution for consumers residing in the states represented by the State Attorney General to compensate consumers who may have paid more than they should have bought for certain generic prescription drugs because of Defendants conduct ("Consumer Restitution Funds"). The State Attorneys General have recovered approximately \$ 25-30 million in Consumer Restitution Funds from Settling Defendants and expect additional settlements and payments.

The proposed Allocation and Distribution Plan ("Plan") is a framework for how the Consumer Restitution Funds will be divided and disbursed among consumers who are eligible to receive distribution from one or more of the Settlements. The Plan identifies which consumers are eligible to receive payment, how much each consumer will receive, and the procedures for processing and paying claims.

WHO IS ELIGIBLE UNDER THE PLAN

5. How Do I Know if I Am Eligible to Receive Payment?

Generally, you are eligible for a payment if at any time from between May 1, 2009 to December 31, 2019 you bought a qualifying generic prescription drug (purchased in the United States and not for resale) manufactured by any of the Defendants and you currently reside in one or more of the following States or other jurisdictions: Connecticut, Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.

Your eligibility for each settlement depends on your current state of residence at the time you submit your claim; eligibility varies across settlements, and residents of some states may be eligible for only certain settlements.

6. What Drug Purchases Qualify?

Qualifying Purchases are purchases of Drugs at Issue during May 1, 2009, through December 31, 2019 (“Time Period”). A list of the drugs at issue in the Settlements, the Allocation and Distribution Plan and the States’ Actions is provided below and available at www.AGGenericDrugs.com or by calling 1-866-290-0182.

7. What Purchases Do Not Qualify?

You are not included if:

- You purchased the drugs outside of the United States;
- You purchased the Drugs at Issue directly from any of the Defendants;
- You purchased the generic drugs for resale or distribution to others; or
- You are an employee of any of the Defendants in the lawsuits and any parent, subsidiary, or affiliate.

8. Who Are the Defendants?

The Defendants are:

- | | |
|--------------------------------------|--|
| • Actavis | • Greenstone LLC |
| • Actavis Holdco U.S., Inc. | • Heritage Pharmaceuticals, Inc. |
| • Actavis Pharma, Inc. | • Lannett |
| • Amneal | • Lannett Company, Inc. |
| • Amneal Pharmaceuticals, Inc. | • Lupin |
| • Apotex Corp. | • Lupin Pharmaceuticals, Inc. |
| • Ascend Laboratories, LLC | • Mallinckrodt |
| • Aurobindo | • Mayne Pharma (USA), Inc. |
| • Aurobindo Pharma USA, Inc. | • Mylan |
| • Bausch | • Mylan Pharmaceuticals, Inc. |
| • Breckinridge Pharmaceuticals, Inc. | • Par Pharmaceutical Companies, Inc. |
| • Citron Pharma, LLC | • Par Pharmaceuticals, Inc. |
| • Dr. Reddy’s Laboratories, Inc. | • Perrigo |
| • Emcure Pharmaceuticals, Ltd. | • Pfizer |
| • Fougera | • Sandoz, Inc. |
| • G&W | • Sun |
| • Glenmark | • Sun Pharmaceutical Industries, Inc. |
| • Glenmark Pharmaceuticals Inc. USA | • Taro |
| • Greenstone | • Taro Pharmaceuticals Industries Ltd. |
| | • Taro USA |
| | • Teligent |

- Teva Pharmaceuticals USA, Inc.
- Upsher-Smith Laboratories, LLC
- Wockhardt
- Wockhardt USA, LLC
- Zydus Pharmaceuticals (USA), Inc.

THE STATES' LITIGATION

9. Why Are the Lawsuits Continuing if There Are Settlements?

Settlements have been reached with some but not all the Defendants. Additional money may become available in the future because of a trial, future settlements, or additional payments required under settlements. Additional proceeds from Non-Settling Defendants are not guaranteed.

Because the lawsuits are continuing against Non-Settling Defendants which may result in future settlements and possible additional money, in addition to submitting a Claim Form (if eligible) please register at the website, www.AGGenericDrugs.com, or call 1-866-290-0182, to be notified of any future settlements, distributions, and other updates from the States' Actions.

THE CLAIMS PROCESS

10. How Do I Participate in the Distribution?

To receive payment, you must submit a valid claim form *before* the claims period ends.

11. What Is the Deadline for Submitting a Claim?

The claims period begins **September 22, 2026** and closes on **March 8, 2027** (the "Claims Deadline").

Only consumers who submit a signed, valid, and complete Claim Form by the Claims Deadline will be entitled to distribution in the Initial Distribution; late but valid claims may be considered in future distributions.

A future final Claims Deadline will bar your participation in any distribution if a valid Claim Form is not submitted by that date, unless otherwise ordered by the Court.

12. How Do I Submit a Claim?

You may submit a Claim Form online at AGGenericDrugsClaims.com. The Claim Form can also be downloaded from the website - www.AGGenericDrugs.com - and submitted by mailing a hard copy to the Claims Administrator (using the address shown on the Claim Form).

13. What Information Do I Need to Provide to Submit a Claim?

The Claim Form requires you to provide your personal information including name, date of birth, mailing address, email, and phone number, and select a preferred payment method (PayPal, Venmo, Zelle, or mailed check).

You must certify that you are an individual, purchased one or more Drugs at Issue in the United States during the Time Period, did not purchase for resale or directly from Defendants, and are not an officer, director, management, or employee of a Defendant or its subsidiaries or affiliates, and you must sign and date the certification.

For most Eligible Consumers, the Claim Form offers two options per settlement for which you are eligible: Option 1 provides an equal share among all Option 1 claimants, and Option 2 provides a share based on your estimated out of pocket spend. Estimated out of pocket spend is the total amount you estimate you paid out of pocket for Drugs at Issue during the Time Period.

If you choose Option 2, you will be required to provide an estimate of your out of pocket spend on the Drugs at Issue during the Time Period. Estimation tips and tools are available at www.AGGenericdrugs.com/English/Estimate. If you choose Option 2, your payment may be higher than the equal share under Option 1, and in all cases will not be less than what you would receive under Option 1. If you choose Option 1, you will not be required to provide an estimate of your out of pocket spend on the Drugs at Issue during the Time Period. If you fail to choose an option, you will be placed into Option 1 by default.

Eligible Consumers residing in Alabama, Arkansas, Hawaii, or Texas, will only receive a payment of a fixed amount to be determined later and funded only from the Apotex settlement. If you reside in Alabama, Arkansas, Hawaii, or Texas, you do not select Option 1 or Option 2.

14. Do I Need to Submit Receipts?

No receipts are required with your Claim Form of your purchases of the Drugs at Issue. If you choose Option 2, the Claims Administrator may later request documentation to corroborate your estimated out of pocket spend (and if so, a lack of documentation could affect an Eligible Consumer's payment).

THE DISTRIBUTION OF PAYMENTS

15. How Much Money Will I Receive?

At this time, how much each Eligible Consumer will receive who submits a signed, valid, and complete Claim Form is unknown, as this will depend on numerous factors, in particular the number and amount of timely, eligible claims submitted, the total money amount available in the Consumer Restitution Fund after receipt of all settlements and/or judgments, and the plan of distribution approved by the Court.

The Claims Administrator will allocate funds per settlement across Option 1 and Option 2 groups (and, for Apotex, an additional allocation for Eligible Consumers in Alabama, Arkansas, Hawaii, or Texas) to ensure an equitable allocation while not exceeding available funds.

16. How Will I Get My Payment?

Payments will be made via your selected method; electronic payment (PayPal, Venmo, or Zelle) is encouraged; mailed checks may be delayed by months due to higher processing and delivery costs and consolidation of payments. Failure to select a method of payment will result in you receiving a check mailed to the address listed on the Claim Form.

17. When Will I Get My Payment?

Payments will be made after the Claims Deadline expires, all timely claims are reviewed, amounts to be paid to different claimants are determined, any disputes are resolved, and the Court grants final approval of the Plan and authorizes payment.

Money will not be distributed until the Court holds a hearing (“Approval Hearing”) and grants final approval of the Allocation and Distribution Plan. The Approval Hearing is set for **September 8, 2027**.

18. Does My Payment Expire?

Once payment is issued by the Claims Administrator, you will have one hundred eighty (180) days to claim the payment. If you *do not* cash your check or accept receipt of the electronic payment within one hundred eighty (180) days, the payment will be cancelled and will remain in the Consumer Restitution Funds and added to the balance available for future distribution to claimants.

You may request reissuance of a cancelled payment within ninety (90) days after expiration and if you do not do so, you lose all claim to that payment and must submit a new updated Claim Form for consideration in future distributions.

THE CLAIMS REVIEW PROCESS AND DENIAL OF CLAIMS

19. What Happens if My Claim Is Incomplete or Deficient?

The Claims Administrator will review all Claim Forms for timeliness, completeness, eligibility, and, where appropriate, corroboration; if your claim is incomplete, deficient, or raises questions, you will be contacted by mail, email, or telephone.

You will have twenty-one (21) calendar days from the date of the Claims Administrator’s communication to provide a complete response or cure deficiencies; failure to timely cure may result in rejection, adjustment, or conversion to an Option 1 claim.

The Claims Administrator or the Court may deny, in whole or in part, any claim if it determines that a Consumer is not eligible to receive distribution from the Consumer Restitution Funds, or if there are legal or equitable grounds for rejection of the claim.

You will be notified of any change to your claim and your right to seek review by the Court.

20. If My Claim Is Denied, Can I Appeal a Denial?

Decisions of the Claims Administrator on disputes (including timeliness, completeness, documentation, calculation, or amount payable) are final, subject to your right to seek review by the Court.

Any appeal must be submitted in writing to the Court, with copies to the Claims Administrator and States' counsel, within twenty-one (21) calendar days of the final rejection notice.

FUTURE DISTRIBUTIONS

21. Will There Be Additional Distributions or Payments?

The State Attorneys General will continue to pursue the lawsuits against the Non-Settling Defendants and will continue to explore additional settlements. All settlement funds allocated as Consumer Restitution Funds will be accumulated in an escrow account and distributed in future distributions, at the conclusion of the lawsuits, or as ordered by the Court.

22. Do I Need to Submit Another Claim Form for Future Distributions?

No. All valid Claim Forms submitted by the Claims Deadline will also be considered for all future distributions.

23. What If I Move After I Submit a Claim?

Your place of residence at the time of submitting your claim determines which settlement funds you may receive from. Moving after filing will not cause you to lose eligibility for distributions already qualified for. You may request review and recalculation if your new residence makes you eligible for additional settlement funds. If so, you would be required to submit a new claim to qualify for payments you previously did not qualify for because of your residence.

REMAINING IN THE STATES ACTIONS

24. What Am I Giving Up If I Stay in the States' Actions?

Unless you exclude yourself, you will be bound by any decisions by the Court relating to the States' Actions, the Allocation and Distribution Plan, and the underlying Settlements from which the restitution money in the Consumer Restitution Fund is derived.

In return for paying the settlement amounts and providing non-monetary benefits, the Settling Defendants will be released for certain claims relating to the facts underlying the States' Actions. The settlement agreements describe the releases, so read them carefully, since those releases will be binding if the Court approves the Settlements. If you have any questions, you can call the toll-free number below or you can talk to your own lawyer (at your own expense) if you have questions about what this means. The settlement agreements and the specific releases are available at www.AGGenericDrugs.com.

EXCLUDE YOURSELF FROM THE ALLOCATION AND DISTRIBUTION PLAN

25. What If I Do Not Want to Be Part of the Allocation and Distribution Plan?

To exclude yourself from the Settlements, the Allocation and Distribution Plan, and the States' Actions go to the website at www.AGGenericDrugs.com, and look for how to exclude yourself (or "Opt Out").

Alternatively, you may exclude yourself by sending a letter (a "Request for Exclusion") by mail to the address below. It must include:

- Your name, address, and telephone number; and
- The cases and cases numbers: *State of Connecticut et al. v. Aurobindo Pharma USA, Inc. et al.*, No. 16-cv-02056 (D. Conn.); *State of Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al.*, No. 19-cv-00710 (D. Conn.); and *State of Connecticut et al. v. Sandoz, Inc. et al.*, No. 20-cv-00802 (D. Conn.); and
- A statement that you want to be excluded from the Allocation and Distribution Plan and the States' Actions; and
- A statement attesting that you have purchased one or more of the Drugs at Issue between May 1, 2009, and December 31, 2019; and
- The date; and
- Your signature.

Your Request for Exclusion must be **postmarked no later than March 8, 2027** (check the website at www.AGGenericDrugs.com for updates on the litigation or register to receive future information), and send to the following address:

**Generic Drugs Settlements Exclusions 8769
P.O. Box 2599
Faribault, MN 55021-9599**

26. What If I Do Not Want to Be Included in the States' Litigation?

The Court has provided a deadline for opting out of the State Attorneys General's litigation in general. To exclude yourself from the States' Actions, go to the website at www.AGGenericDrugs.com, and look for how to exclude yourself (or "Opt Out").

Alternatively, you may exclude yourself by sending a letter (a "Request for Exclusion") by mail to the address below. It must include:

- Your name, address, and telephone number; and
- The cases and cases numbers: *State of Connecticut et al. v. Aurobindo Pharma USA, Inc. et al.*, No. 16-cv-02056 (D. Conn.); *State of Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al.*, No. 19-cv-00710 (D. Conn.); and *State of Connecticut et al. v. Sandoz, Inc. et al.*, No. 20-cv-00802 (D. Conn.); and
- A statement that you want to be excluded from the States' Actions; and
- A statement attesting that you have purchased one or more of the Drugs at Issue between May 1, 2009, and December 31, 2019; and
- The date; and
- Your signature.

Your Request for Exclusion must be **postmarked no later than March 8, 2027** (check the website at www.AGGenericDrugs.com for updates on the litigation or register to receive future information), and send to the following address:

**Generic Drugs Settlements Exclusions 8769
P.O. Box 2599
Faribault, MN 55021-9599**

OBJECTING TO THE ALLOCATION AND DISTRIBUTION PLAN

27. How Do I Object to the Allocation and Distribution Plan?

If you have objections to any aspect of the Allocation and Distribution Plan, you may express your views to the Court by writing to the address below. It must include:

- Your name, address, telephone number, and an explanation of your objection; and
- The case name and number: *State of Connecticut et al. v. Aurobindo Pharma USA, Inc. et al.*, No. 16-cv-02056 (D. Conn.); *State of Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al.*, No. 19-cv-00710 (D. Conn.); and *State of Connecticut et al. v. Sandoz, Inc. et al.*, No. 20-cv-00802 (D. Conn.); and
- A statement attesting that you have purchased one or more of the Drugs at Issue between May 1, 2009, to December 31, 2019; and
- The date; and
- Your signature; and
- The name, address, and telephone number of any lawyer assisting you.

In addition, if you object you may be asked for additional information, including:

- Documentation demonstrating that you are or were a resident of one the States, Commonwealths, Territories, or the District of Columbia currently involved in the States' Actions, followed by your signature: "I declare that [insert your name] is a resident of a State, Commonwealth, [...]"; and
- Documentation demonstrating that you bought a qualifying generic prescription drug (not for resale), including the date(s) of purchase.

Any objection must be mailed to these four addresses and **received by the Court no later than March 8, 2027**:

COURT	COUNSEL FOR THE STATE ATTORNEYS GENERAL	COUNSEL FOR DEFENDANTS
Clerk's Office Abraham Ribicoff Federal Building United States Courthouse 450 Main Street Suite A012 Hartford, CT 06103	Saami Zain Assistant Attorney General New York Attorney General 28 Liberty Street, New York, NY 10005	Michael B. Miller Robert W. Manoso Morrison Foerster 250 W. 55 th Street New York, NY 10019 (Counsel for Glenmark)

		Robin D. Adelstein Mark A. Robertson Norton Rose Fulbright US LLP 1301 Avenue of the Americas New York, NY 10019 (Counsel for Bausch) George G. Gordon Dechert LLP 2929 Arch Street Philadelphia, PA 19104-2808 (Counsel for Lannett) April Williams Wilmer Hale 2100 Pennsylvania Avenue NW Washington, DC 20037 (Counsel for Apotex) Gregory D. Vose Reed Smith LLP Antitrust, Litigation & Consumer Protection Reed Smith Centre, 225 Fifth Avenue Pittsburgh, PA, 15222 (Counsel for Heritage)
--	--	--

If you hire a lawyer to make an objection, your lawyer must also file a Notice of Appearance with the Clerk of the Court **no later than March 8, 2027**.

28. What Is the Difference Between Objecting to the Allocation and Distribution Plan and Excluding Myself from the Allocation and Distribution Plan and States' Actions?

Objecting to the Allocation and Distribution Plan simply means telling the Court that you do not like something about the Allocation and Distribution Plan or have certain concerns about the Allocation and Distribution Plan. Objecting does not disqualify you from making a claim nor does it make you ineligible to receive a payment.

If you exclude yourself from the Allocation and Distribution Plan or the States' Actions, you are no longer part of the Allocation and Distribution Plan or the States' Actions. Therefore, you will not be eligible to receive any payments from the States' Actions, and you will not be able to object to the Allocation and Distribution Plan. You will not be subject to the terms and conditions of the Settlements.

THE FINAL APPROVAL HEARING

29. When and Where Will the Court Decide Whether to Approve the Allocation and Distribution Plan?

The Court will hold a Final Approval Hearing on the Allocation and Distribution Plan on **September 8, 2027, at 10:00 a.m.**, at the Abraham Ribicoff Federal Building, United States Courthouse, 450 Main Street – Annex 135, Hartford, Connecticut 06103, Courtroom 3. The hearing may be moved to a different date or time without additional notice, so check www.AGGenericDrugs.com for current information or call 1-866-290-0182 if you want to find out if the hearing has been rescheduled. At the Fairness Hearing, the Court will consider whether the Allocation and Distribution Plan is fair, reasonable, and adequate. If there are objections or comments, the Court will consider them at that time. After the hearing, the Court will decide whether to grant final approval to the Allocation and Distribution Plan. We do not know how long these decisions will take.

Subsequent Settlements will be scheduled for final approval hearings at future dates. Check www.AGGenericDrugs.com for current information or call 1-866-290-0182 for updated information regarding final approval hearings.

30. Do I Have to Attend the Final Approval Hearing?

No. Counsel for the State Attorneys General will be prepared to answer questions about the Allocation and Distribution Plan. Individuals who have filed and served written objections may (but do not have to) appear at the Final Approval Hearing, in person or through an attorney hired at their own expense.

31. Can I Attend the Final Approval Hearing?

Yes. Anyone can attend the Final Approval Hearing and watch. If you want to attend and observe, you do not have to do anything.

If you want to attend and object, in-person or through an attorney hired at your own expense, you need to mail a written Notice of Intent to Appear to the address listed in Question 28 so that it is received by **March 8, 2027**. The Notice of Intent to Appear must contain the following information:

1. Your name, address, and telephone number and, if applicable, the name, address, and telephone number of your attorney (who must file a Notice of Appearance with the Clerk of the Court not later than **March 8, 2027**);
2. Your comments or objection, including any supporting papers; and
3. The name and addresses of any witnesses that you will present at the Final Approval Hearing, together with a statement as to the matters on which they wish to testify and a summary of the proposed testimony.

GET MORE INFORMATION

32. Where Can I Get More Information?

This Notice summarizes the Allocation and Distribution Plan. You can get more information about the Allocation and Distribution Plan, the States' Actions, and the Settlements at www.AGGenericDrugs.com,

by calling 1-866-290-0182, sending an email to info@aggenericdrugs.com, or writing to Generic Drugs Settlements 8769, P.O. Box 2599, Faribault, MN 55021-9599.

You can also get copies of the official Court file by accessing the Court docket in this case:

- Through the Court's Public Access to Court Electronic Records (PACER) system at <https://pacer.login.uscourts.gov>, or
- By visiting the office of the Clerk of the Court for the United States District Court for the District of Connecticut, Abraham Ribicoff Federal Building, United States Courthouse, 450 Main Street, Suite A012, Hartford, CT 06103, between 9:00 a.m. and 4:00 p.m., Monday through Friday, excluding Court holidays.

PLEASE DO NOT TELEPHONE THE COURT OR THE COURT CLERK'S OFFICE TO INQUIRE ABOUT THE ALLOCATION AND DISTRIBUTION PLAN OR THE CLAIM PROCESS.

DRUGS AT ISSUE

More information on the List of Drugs can be found at <https://AGGenericdrugs.com/English/Drug-List>

Acetazolamide
Acetazolamide Tablet 125 mg
Acetazolamide Tablet 250 mg
Adapalene Cream 0.1%
Adapalene Gel
Alclometasone Dipropionate Cream 0.05%
Alclometasone Dipropionate Ointment
Amiloride HCL/HCTZ Tablets
Ammonium Lactate Cream EQ 12% Base
Ammonium Lactate Lotion EQ 12% Based
Amoxicillin/Clavulanate Chewable Tablets
Amphetamine/Dextroamphetamine ER (aka Mixed Amphetamine Salts)
Amphetamine/Dextroamphetamine IR
Azithromycin Suspension
Azitlnomycin Oral Suspension
Baclofen Tablets
Benazepril HCTZ
Betamethasone Dipropionate Cream EQ 0.05% BASE
Betamethasone Dipropionate Cream, Augmented EQ 0.05% BASE
Betamethasone Dipropionate Lotion EQ 0.05% BASE
Betamethasone Dipropionate Lotion, Augmented EQ 0.05% BASE
Betamethasone Valerate Cream 0.01% BASE
Betamethasone Valerate Lotion 0.01% BASE
Betamethasone Valerate Ointment 0.01% BASE
Betamethasone Valerate Tablet 0.01% BASE
Bethanechol Chloride Tablets
Bromocriptine Mesylate Tablets EQ 2.5 mg Base
Budesonide DR Capsules
Budesonide Inhalation
Bumetanide Tablets
Buspirone Hydrochloride Tablets
Cabergoline
Calcipotriene Betamethasone Dipropionate Ointment 0.06-0.005%
Calcipotriene Solution 0.005%
Capecitabine
Carbamazepine Chewable Tablets
Carbamazepine ER Tablets 100mg; 200mg; 400mg
Carbamazepine Tablets
Cefdinir Capsules
Cefdinir Oral Suspension
Cefpodoxime Proxetil Oral Suspension EQ 100mg Base; EQ 50mg Base
Cefpodoxime Proxetil Tablets EQ 100mg Base; EQ 200 mg Base
Cefprozil Tablets
Celecoxib
Cephalexin Suspension
Chlorpromazine HCL

Cholestyramine
 Ciclopirox Cream 0.77%
 Ciclopirox Shampoo 1%
 Ciclopirox Solution 8%
 Cimetidine Tablets
 Ciprofloxacin Tablets
 Clarithromycin ER Tablets
 Clemastine Fumarate Tablets
 Clindamycin Phosphate 60 ml solution
 Clindamycin Phosphate All except solution (Cream, Gel, Lotion)
 Clindamycin Phosphate All formulations (Cream, Gel, Lotion, Solution)
 Clobetasol Propionate Cream 0.05%
 Clobetasol Propionate Gel 0.05%
 Clobetasol Propionate Ointment 0.05%
 Clobetasol Propionate Solution 0.05%
 Clomipramine HCL
 Clonidine TTS Patch
 Clotrimazole Betamethasone Dipropionate Cream EQ 0.05% BASE
 Clotrimazole Betamethasone Dipropionate Ointment EQ 0.05% BASE
 Clotrimazole Topical Solution
 Cyproheptadine HCL Tablets
 Desmopressin Acetate-Tablets
 Desogestrel/Ethinyl Estradiol Tablets (Kariva)
 Desonide Cream 0.05%
 Desonide Lotion 0.05%
 Desonide Ointment 0.05%
 Desoximetasone Ointment 0.05%; 0.25%
 Dexmethylphenidate
 Dextroamphetamine Sulfate ER
 Diclofenac Potassium Tablets
 Diclofenac Tablets
 Dicloxacillin Sodium Capsules
 Diflunisal Tablets
 Diltiazem HCL Tablets
 Disopyramide Phosphate Capsules
 Doxazosin Mesylate Tablets
 Doxycycline hyclate DR
 Doxycycline monohydrate
 Drospirenone and ethinyl estradiol (Ocella)
 Econazole Nitrate Cream 1%
 Enalapril Maleate Tablets
 Entecavir
 Epitol Tablets
 Eplerenone Tablets 25mg; 50mg
 Erythromycin Base/Ethyl Alcohol Solution 2%
 Estazolam Tablets
 Estradiol
 Estradiol Tablets
 Ethambutol HCL [hydrochloride] Tablets 100mg; 400mg
 Ethinyl estradiol and levonorgestrel (Portia and Jolessa)
 Ethosuximide Capsules

Ethosuximide Oral Solution
 Etodolac ER Tablets
 Etodolac Tablets
 Fenofibrate
 Fluconazole Tablets
 Fluocinolone Acetonide Cream 0.01%; 0.025%
 Fluocinolone Acetonide Ointment 0.025%
 Fluocinonide Cream
 Fluocinonide Cream 0.05%; 0.1%
 Fluocinonide Emollient Cream
 Fluocinonide Gel
 Fluocinonide Gel 0.05%
 Fluocinonide Ointment
 Fluocinonide Ointment 0.05%
 Fluocinonide Solution 0.05%
 Fluoxetine HCL Tablets
 Flurbiprofen Tablets
 Flutamide Capsules
 Fluticasone Propionate Lotion (60ml) 0.05%
 Fluvastatin Sodium Capsules
 Fosinopril-hydrochlorothiazide
 Gabapentin Tablets
 Glimepiride Tablets
 Glipizide-metformin
 Glyburide
 Glyburide-metformin
 Griseofulvin Microsize Tablets 250mg; 500mg
 Griseofulvin Suspension
 Halobetasol Propionate Cream 0.05%
 Halobetasol Propionate Ointment 0.05%
 Haloperidol
 Hydrocortisone Acetate Suppositories (Anucort HC) Suppository 25mg; 30mg
 Hydrocortisone Valerate Cream 0.2%
 Hydroxyurea Capsules
 Hydroxyzine Pamoate Capsules
 Imiquimod Cream 0.2%
 Irbesartan
 Isoniazid
 Ketoconazole Cream
 Ketoconazole Cream 2%
 Ketoconazole Tablets
 Ketoprofen Capsules
 Ketorolac Tromethamine Tablets
 Labetalol HCL Tablets
 Lamivudine/Zidovudine (generic Combivir)
 Latanoprost Drops/Solution 0.005%; 0.01%
 Leflunomide
 Levothyroxine
 Lidocaine Ointment 5%
 Loperamide HCL Capsules
 Medroxyprogesterone Tablets

Meprobamate
 Methazolamide Tablets 25mg; 50mg
 Methotrexate Tablets
 Methylphenidate HCL ER Tablets 10mg; 20mg; 5mg
 Methylphenidate HCL Tablets 10mg; 20mg; 5mg
 Metronidazole Cream 0.75%
 Metronidazole Gel 0.75%
 Metronidazole Gel 1%
 Metronidazole Lotion 0.75%
 Mimvey (Estradiol/Noreth) Tablets
 Moexipril HCL Tablets
 Moexipril HCL/HCTZ Tablets
 Mometasone Furoate Cream 0.1%
 Mometasone Furoate Ointment 0.1%
 Mometasone Furoate Solution 0.1%
 Nabumetone Tablets
 Nadolol Tablets
 Nafcillin Sodium Injectable Vials EQ 10GM Base; EQ 1GM Base; EQ 2GM Base
 Niacin ER Tablets
 Nimodipine
 Nitroforantoin MAC Capsules
 Norethindrone/ethinyl estradiol (Balziva)
 Northindrone Acetate
 Nortriptylline Hydrochloride Capsules
 Nystatin
 Nystatin Ointment 100,000 UNITS/GM
 Nystatin/Triamcinolone Acetonide Cream - 100,000 UNITS/GM, 0.1%; 100,000 UNITS/GM, 1%
 Nystatin/Triamcinolone Acetonide Ointment -100,000 UNITS/GM, 0.1%; 100,000 UNITS/GM, 1%
 Omega-3-Acid Ethyl Esters
 Oxacillin Sodium Injectable Vials - EQ 10GM Base; EQ 1GM Base; EQ 2GM Base
 Oxaprozin Tablets
 Oxybutynin Chloride Tablets
 Paricalcitol
 Paromomycin
 Penicillin VK Tablets
 Pentoxifylline Tablets
 Phenytoin Sodium ER Capsule – 100mg; 200mg; 300mg
 Pioglitazone HCL Metformin HCl Tablets 500mg, EQ 15mg Base; 850MG; EQ 15mg Base
 Piroxicam
 Pravastatin Sodium Tablets
 Prazosin HCL Capsules
 Prochlorperazine Maleate Suppository – 25mg
 Prochlorperazine Tablets
 Promethazine HCL Suppositories 12.5mg; 25mg
 Propranolol HCL Tablets
 Raloxifene HCL Tablets
 Ranitidine HCL Tablets
 Tacrolimus Ointment – 0.03%; 0.1%
 Tamoxifen Citrate Tablets
 Temozolomide
 Terconazole Cream 0.8%

Theophylline
Tizanidine
Tobramycin
Tolmetin Sodium Capsules
Tolterodine ER
Tolterodine Tartrate
Topiramate Sprinkle Capsules
Triamcinolone Acetonide
Triamcinolone Acetonide Cream - 0.8%; 0.025%; 0.1%; 0.5%
Triamcinolone Acetonide Ointment - 0.025%; 0.1%; 0.5%
Triamcinolone Acetonide Paste – 0.1%
Trifluoperazine HCL
ValsartanHCTZ
Verapamil
Warfarin Sodium Tablets
Zoledronic acid